Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 5:39 PM
Ignite Modification Date:
2025-12-24 @ 5:39 PM
NCT ID:
NCT03687268
Brief Summary:
Prospective, randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre, phase III trial of Naloxone HCl PR Tablets (12 mg and 24 mg) administered twice daily.
The trial will consist of four phases:
Screening phase (Week -4 to Week -3):
Confirmation phase (Week -2 to Week -1):
Double-blind treatment phase
Follow-up phase (Week 13-14):
Study:
NCT03687268
Study Brief:
Protocol Section:
NCT03687268